Drug combinations key in treating neurodegenerative diseases

Jan 30, 2009

Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases, Medical College of Georgia researchers say.

Drugs that protect neurons, for example, can be used with those targeting memory to make real progress in treating diseases such as Alzheimer's, says Dr. Jerry Buccafusco, founding director of the MCG Alzheimer's Research Center.

"We realize that with neurodegenerative diseases there will not be one magic bullet," Dr. Buccafusco says. "Developing new therapeutics will require an attack on many different levels. But, right now, there are no FDA-approved compounds out there that are significantly disease-modifying. We're at the point where we're just getting to that."

His review of trends in pharmacological research of neurodegenerative diseases is the featured article in the January issue of NeuroTherapeutics, the journal of the American Society for Experimental NeuroTherapeutics.

Alzheimer's treatment, for instance, should combine molecules that protect neurons from plaque buildup with approved therapies like cholinesterase inhibitors, which treat cognition and memory loss, Dr. Buccafusco says.

Dr. Buccafusco also cited several novel drug candidates developed at the MCG Alzheimer's Research Center, including two molecules prevent cell death in the brain and improve cognition, reaction time and attention.

"What we have to do now is look at drugs that have already been developed to address very specific disease targets and come up with new ways to combine constituent groups of active molecules into a single therapeutic agent," Dr. Buccafusco says. "Drugs should target more than one particular molecular structure and molecular receptor in the central nervous system. The technology is available to design molecules that have multiple properties all in one package. This approach could represent a new frontier for pharmacology."

Advantages to multi-functional drug compounds, he says, include fewer side effects.

Source: Medical College of Georgia

Explore further: Sierra Leone faces criticism over Ebola shutdown

add to favorites email to friend print save as pdf

Related Stories

NASA HS3 instrument views two dimensions of clouds

50 minutes ago

NASA's Cloud Physics Lidar (CPL) instrument, flying aboard an unmanned Global Hawk aircraft in this summer's Hurricane and Severe Storm Sentinel, or HS3, mission, is studying the changing profile of the atmosphere ...

Recommended for you

Sierra Leone faces criticism over Ebola shutdown

6 hours ago

Sierra Leone began the second day of a 72-hour nationwide shutdown aimed at containing the spread of the deadly Ebola virus on Saturday amid criticism that the action was a poorly planned publicity stunt.

Presence of peers ups health workers' hand hygiene

20 hours ago

(HealthDay)—The presence of other health care workers improves hand hygiene adherence, according to a study published in the October issue of Infection Control and Hospital Epidemiology.

Sierra Leone streets deserted as shutdown begins

Sep 19, 2014

Sierra Leone's normally chaotic capital resembled a ghost town on Friday as residents were confined to their homes for the start of a three-day lockdown aimed at halting the deadly Ebola epidemic.

Sierra Leone launches controversial Ebola shutdown

Sep 19, 2014

Sierra Leone on Friday launched a controversial three-day shutdown to contain the deadly spread of the Ebola virus, as the UN Security Council declared the deadly outbreak a threat to world peace.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
not rated yet Feb 01, 2009
This is great but one has to remember what was not said and the real driving force behind this work: "Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases... and extending the earning power of a variety of older drugs for big pharma.